eCOA, eSource and Clinical Trials Global Market Report 2024

The ecoa, esource & clinical trials market size has grown strongly in recent years. It will grow from $44.85 billion in 2023 to $48.94 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period can be ascribed to the widespread adoption of electronic data capture in clinical trials, the development of regulatory standards for electronic clinical outcome assessments (eCOA), the expansion of mobile and wearable health technology, the rising complexity and scale of clinical trials, and the increased emphasis on patient-centric approaches in clinical research.

The ecoa, esource & clinical trials market size is expected to see strong growth in the next few years. It will grow to $67.33 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be linked to the global expansion of clinical trial networks, an increased demand for real-time data access and monitoring, the emergence of cloud-based eClinical solutions, the proliferation of remote and virtual patient monitoring solutions, a rise in the utilization of electronic patient-reported outcomes, an upswing in the adoption of wearables for continuous patient monitoring, a surge in the use of mobile health apps for patient engagement, and a focus on user-friendly and patient-centric eCOA designs. Noteworthy trends expected in the forecast period include technological advancements in eSource solutions, the adoption of blockchain for secure and transparent clinical data management, the integration of artificial intelligence for data analysis in clinical research, the adoption of machine learning for predictive analytics in clinical trials, and the development of decentralized clinical trial ecosystems.

The anticipated surge in clinical trials is expected to drive the growth of the eCOA, eSource, and clinical trials market. Clinical trials, which are research studies assessing the safety and efficacy of new medical interventions or treatment approaches, can benefit from the use of eCOA and eSource solutions. These technologies enable pharmaceutical companies to expedite trials, conducting them more efficiently within shorter time frames. eCOA solutions replace traditional paper-based patient-reported outcomes by employing innovative technologies for collecting clinical outcome data. For example, a report published on ClinicalTrials.gov in June 2023, a US-based registry of clinical trials run by the United States National Library of Medicine, projects the number of registered studies to reach 457,100 in 2023, a substantial increase from 362,479 in 2020. Thus, the growing demand for more clinical trials is a driving force behind the expansion of the eCOA, eSource, and clinical trials market.

The increasing adoption of cloud-based solutions is poised to propel the future growth of the eCOA, eSource, and clinical trials market. Cloud-based solutions encompass programs, storage spaces, on-demand services, computer networks, and other services accessible through a shared cloud computing framework via an internet connection. These solutions streamline eCOA (electronic Clinical Outcome Assessments) and eSource in clinical trials by facilitating real-time data capture, secure storage, and remote accessibility, ultimately optimizing trial efficiency and ensuring data accuracy. As an example, according to the Australian Bureau of Statistics in June 2023, an Australia-based government agency for statistics, 85% of firms reported employing information and communication technologies (ICTs) for the year ending June 30, 2022, up from 69% during the year ending June 30, 2020, with 59% related to cloud computing. Hence, the increasing adoption of cloud-based solutions is a driving factor for the growth of the eCOA, eSource, and clinical trials market.


Technological advancements constitute a prominent trend gaining traction in the eCOA, eSource, and clinical trials market. Leading companies in these markets are actively engaged in introducing innovative technologies to maintain their competitive positions. For example, in May 2022, Clinical Research IO, a US-based developer of eSource solutions, unveiled CRIO Reviewer, an industry-first solution designed to establish a fully integrated eSource or EDC (electronic data capture) system. This solution facilitates the review and coding of data collected by the CRIO eSource application, utilizing CRIO's web-based resource technology to optimize site workflows in clinical data management. As the first commercial system designed for site processes, CRIO Reviewer aims to make real-time electronic data gathering more accessible for sites.

Major companies in the eCOA, eSource, and clinical trials market are directing their efforts toward advanced solutions, including cutting-edge study design technology, to enhance the efficiency and accuracy of data collection for improved clinical trial outcomes and patient-centric experiences. Advanced study design technology involves leveraging innovative methodologies, such as adaptive trials and AI-driven analytics, to enhance research precision and efficiency in exploring scientific hypotheses and gathering robust data. In June 2021, ObvioHealth, a US-based digital clinical trials company, launched an innovative electronic clinical outcome assessment (eCOA) solution that seamlessly integrates advanced study design technology. This solution combines scientific advisory with a no-code study design platform and a virtual site for more real-time and robust data capture. The eCOA design technology includes the programming of patient engagement tactics, such as push notifications and a custom chat feature for support.

In May 2021, Validant, a US-based provider of regulatory, compliance, and quality consulting services, completed the acquisition of Clinical Outcomes Solutions for an undisclosed amount. This strategic move aligns with Validant's growth strategy and expands the company's consumer base. Clinical Outcomes Solutions is a US-based provider of electronic and manual clinical outcome assessment services.

Major companies operating in the ecoa, esource and clinical trials market report are The International Business Machines Corporation, Oracle Corporation, Novo Nordisk A/S, Laboratory Corporation of America Holdings, IQVIA Inc., Icon PLC, PPD Inc., Syneos Health Inc, Parexel International Corporation, Medpace Holdings Inc., TransPerfect Life Sciences, Medidata Solutions Inc., Signant Health Private Limited, Clario, Advarra Inc., Medable Inc., ArisGlobal LLC, Kayentis SAS, YPrime LLC, Clinical Ink, Cloudbyz Inc., Medrio Inc., assisTek Inc., OpenClinica LLC, Castor EDC, Clinipace Inc, Hospira Inc.

North America was the largest region in the eCOA, eSource and clinical trials market in 2023. The regions covered in the ecoa, esource and clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ecoa, esource and clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary solution categories encompassed by eCOA, eSource, and clinical trials include eCOA (Electronic Clinical Outcome Assessment), eSource, clinical trial solutions, and electronic data capture (EDC). eCOA, specifically, entails utilizing electronic systems and devices to capture, manage, and analyze patient-reported outcome measures within clinical trials and healthcare settings. This solution can be deployed in both licensed enterprise (on-premise) and cloud-based (SAAS) environments, catering to diverse end users such as hospitals, healthcare providers, Contract Research Organizations (CROs), the pharmaceutical industry, the biotechnology industry, the medical device industry, and others.

The eCOA, eSource and clinical trials market research report is one of a series of new reports that provides eCOA, eSource and clinical trials market statistics, including eCOA, eSource and clinical trials industry global market size, regional shares, competitors with a eCOA, eSource and clinical trials market share, detailed eCOA, eSource and clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the eCOA, eSource and clinical trials industry. This eCOA, eSource and clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eCOA, eSource, and clinical trials markets include revenues earned by entities by providing pre-built assessments, real-time patient data, and project documentation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.